Enliven Therapeutics (ELVN) Net Cash Flow Growth (3y) (2022 - 2026)
Enliven Therapeutics (ELVN) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 32.17% |
| 10 | Enliven Therapeutics | 3.40 Bn | 2.95 Bn | - | -46.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.43% |
| Dec 31, 2025 | 35.61% |
| Sep 30, 2025 | -41.14% |
| Jun 30, 2025 | 63.73% |
| Mar 31, 2025 | -30.34% |
| Dec 31, 2024 | 42.12% |
| Sep 30, 2024 | -48.38% |
| Jun 30, 2024 | -114.25% |
| Mar 31, 2024 | 104.37% |
| Dec 31, 2023 | 24.76% |
| Sep 30, 2023 | -36.28% |
| Jun 30, 2023 | -73.12% |
| Mar 31, 2023 | 38.35% |
| Dec 31, 2022 | 4.38% |
| Sep 30, 2022 | 39.29% |
| Jun 30, 2022 | -28.47% |
| Mar 31, 2022 | -30.93% |